Federal Circuit Rules for The Medicines Company in Patent Litigation
In an en banc decision on July 12, 2016 in The Medicines Co. v. Hospira, Inc ., the Federal Circuit established the circumstances under which a product manufactured according to product-by-process claims is invalid under the “on sale” bar of 35…
August 12, 2016Federal Circuit4 min read